# MilliporeSigma invests €300M in new bioprocessing site in Daejeon, South Korea

MilliporeSigma, the Life Science business of Merck KGaA, is investing more than €300 million to build a new Bioprocessing Production Center in Daejeon, South Korea, expected to create up to 300 jobs by 2028.

- Type: New facility
- Announced: 2024-03-20
- Where: Daejeon, South Korea, South Korea
- Value: $326.0M (300.0M EUR)
- Jobs: 300
- Starts operating: 2028
- Status: announced
- Capacity: 43,000 square meters
- Products: dry powder cell culture media, process liquids, sterile sampling systems, biotech products for biologics
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [MilliporeSigma](https://endata.com/companies/7341.md)
- [Merck KGaA](https://endata.com/companies/1393.md) (investor)
- [Merck KGaA](https://endata.com/companies/1393.md) (partner)

## Sources

- [wolfmediausa.com](https://wolfmediausa.com/2024/03/20/news-release-milliporesigma-invests-more-than-e-300-million-in-new-life-science-production-site-in-korea/), 2024-03-20: "The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date."
- [businesswire.com](https://www.businesswire.com/news/home/20240320070934/en/MilliporeSigma-Invests-More-than-%E2%82%AC-300-Million-in-New-Life-Science-Production-Site-in-Korea), 2024-03-20: "The Asia-Pacific region is home to a large number of institutions that conduct leading-edge and innovative research, manufacturing and services in areas such as biotechnology, mRNA and gene therapy."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.